BMC Nephrology · 2022 · 25 citations · 20 references
MedicineImmunologyPathobiologyAutoimmunityImmunopathologyInflammationRenal DiseaseSystemic Lupus ErythematosusVitamin BiochemistryVitamin DVitamin D MetabolismVitamin PhysiologyLupus Nephritis TherapyMapk SignalingMitogen-activated Protein Kinase SignalingNuclear Factor Kappa B ActivationNuclear Factor Kappa B InhibitionNuclear Factor Kappa B ModulationNuclear Factor Kappa B SignalingVitamin D Metabolites
BACKGROUND: Lupus nephritis (LN) is a common and serious complication of systemic lupus erythematosus (SLE). However, the aetiology and pathogenesis of LN remain unknown. 1,25-dihydroxyvitamin D3 [1,25-(OH)2-VitD3] is the active form of vitamin D, and it has been shown to perform important functions in inflammatory and immune-related diseases. In this study, we investigated the time-dependent effects of 1,25-dihydroxyvitamin D3 and explored the underlying mechanism in MRL/lpr mice, a well-studied animal model of LN. METHODS: Beginning at 8 weeks of age, 24-h urine samples were collected weekly to measure the levels of protein in the urine. We treated female MRL/lpr mice with 1,25-dihydroxyvitamin D3 (4 μg/kg) or 1% DMSO by intraperitoneal injection twice weekly for 3 weeks beginning at the age of 11 weeks. The mice were separately sacrificed, and serum and kidney samples were collected at the ages of 14, 16, 18, and 20 weeks to measure creatinine (Cr) levels, blood urea nitrogen (BUN) levels, histological damage, immunological marker (A-ds DNA, C1q, C3, IgG, IgM) levels, and inflammatory factor (TNF-α, IL-17, MCP-1) levels. Furthermore, the nuclear factor kappa B (NF-κB) and the mitogen-activated protein kinase (MAPK) signalling pathways were also assessed to elucidate the underlying mechanism. RESULTS: We found that MRL/lpr mice treated with 1,25-dihydroxyvitamin D3 displayed significantly attenuated LN. VitD3-treated mice exhibited significantly improved renal pathological damage and reduced proteinuria, BUN, SCr, A-ds DNA antibody and immune complex deposition levels (P < 0.05) compared with untreated MRL/lpr mice. Moreover, 1,25-dihydroxyvitamin D3 inhibited the complement cascade, inhibited the release of proinflammatory cytokines, such as TNF-α, IL-17, and MCP-1, and inhibited NF-κB and MAPK activation (P < 0.05). CONCLUSION: 1,25-dihydroxyvitamin D3 exerts a protective effect against LN by inhibiting the NF-κB and MAPK signalling pathways, providing a potential treatment strategy for LN. Interestingly, the NF-κB and MAPK signalling pathways are time-dependent mediators of LN and may be associated with lupus activity.
20
Histologic versus clinical remission in proliferative lupus nephritis
Ana Malvar, Paola Pirruccio, Valeria Albertón et al. · Nephrology Dialysis Transplantation · 2015 · 253 citations · Full text
Medicine, Nephrology, Pathology +17
Guillermo Pérez de Lema, Holger Maier, Elena Nieto et al. · Journal of the American Society of Nephrology · 2001 · 244 citations
Medicine, Immunology, Pathobiology +17
Mamiko Kobayashi, Daisuke Mikami, Hideki Kimura et al. · Biochemical and Biophysical Research Communications · 2017 · 217 citations